Please assess the completion status of the following clinical trial:

Trial Title: Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be included if they comply with the following inclusion criteria determined at baseline, prior to first drug administration:~* Aged over 18 years.~* Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction). All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years).~* Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score will be from 3 to 8 (mild: 3-5 or moderate: 6-8).~* Men or non pregnant women.~* Women with childbearing potential must be using a contraceptive method judged effective by the investigator.~* Oral maintenance treatment with azathioprine or 6-mercaptopurine (taken for at least 6 months at stable dose and continued at the same dose throughout the study) is permitted.~* Informed consent given.~Exclusion Criteria:~The patients will not be included in the study if one of the following exclusion criteria is fulfilled at baseline, prior to first drug administration:~* Proctitis (less than 12-18 cm from the anorectal junction).~* Previous colonic surgery.~* Previously failed to respond to steroids within the previous year.~* Non-response to rectal 5-Amino Salicylic Acid (5-ASA) therapy or to oral 5-ASA therapy at a dose \> 3g/day for induction of remission within the previous year.~* Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says).~* Severe/fulminant ulcerative colitis.~* Evidence of other forms of inflammatory bowel disease or infectious disease.~* Allergy to aspirin or salicylate derivatives.~* The following treatment will be forbidden during the study (if present at selection, a wash-out will be necessary):~* Loperamide and other antidiarrheal agents, mucilages, antibiotics: 1 week wash-out.~* Oral steroids: 4 weeks wash-out.~* Rectal steroids: 2 weeks wash-out~* Repeated treatment (\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardioprotection is allowed).~* Sulfasalazine \> 4g/day or mesalazine or 4-ASA at a higher dose than what is permitted in the local formulary or standard care for maintenance treatment: 4 weeks wash-out~* Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above).~* Known significant hepatic or renal function abnormalities.~* Moderate/severe abnormal renal, hepatic or blood count tests defined as: creatinine plasma value \> 1.5 x Upper Limit of Normal (ULN) or white blood cells \< 3500/mm˄3 or \> 15000/mm˄3 or Platelets \< 100000/mm˄3 or \> 800000/mm˄3 or aspartate aminotransferase/alanine Aminotransferase (ASAT/ALAT) \> 3 x ULN or Gamma glutamyl transpeptidase (GGT)/Alkaline Phosphatase's \> 3 x ULN (Primary Sclerosing Cholangitis is not an exclusion criteria).~* History or physical examination findings indicative of active alcohol or drug abuse,~* Pregnancy or breast-feeding,~* History of disease, including mental/emotional disorder, that might interfere with their participation in the study,~* Participation in another clinical study in the last 3 months.~* Inability to comply with the protocol requirements.~* Inability to fill in the diary cards.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesalazine once/day (Type: EXPERIMENTAL): Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
- Mesalazine twice/day (Type: ACTIVE_COMPARATOR): Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).

Based on this trial design, predict the completion outcome and termination type (if applicable).